Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting.
Clopidogrel, an adenosine diphosphate receptor blocker, is widely used as an adjunctive antiplatelet therapy in acute coronary syndrome and percutaneous coronary stenting. The occurrence of hepatotoxicity is rare. We describe the occurrence of symptomatic liver disease in a 74-year-old man 5 weeks following commencement of therapy with clopidogrel. The reported cases of clopidogrel-induced hepatotoxicity are reviewed and the clinical significance of this event are discussed.
Chau
T N
TN
Department of Medicine and Geriatrics, United Christian Hospital, Kwun Tong, Hong Kong. chautainin@hotmail.com
Yim
K F
KF
Mok
N S
NS
Chan
W K
WK
Leung
V K S
VK
Leung
M F
MF
Lai
S T
ST
D000368:Aged; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015607:Stents; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine